Takeda UK and Nipro Diagnostics have entered into a long-term pact to co-promote a range of the latter group’s blood glucose monitoring systems within the UK.
Under the alliance, Nipro will work alongside Takeda’s UK sales force to “facilitate the communication of the benefits of the TRUEresult and TRUEyou range of glucose monitoring devices to NHS primary care organisations”, the firms said in a statement.
More specific details of the arrangement were not revealed, but it was noted that the move enables Takeda to expand its portfolio of products in the diabetes therapy area, and “significantly” increases Nipro’s visibility in the UK.
Chris Avery, Nipro Diagnostics’ Managing Director, noted that its partnership with Takeda, which has a “broad base of established relationships with key stakeholders within diabetes,” will help the group to “serve [its] customers and patients even better”.
Yasuhiro Fukutomi, Managing Director of Takeda UK, said the alliance “will be successful for both companies and will bring benefits to patients and the NHS”.
According to Nipro, its blood glucose management systems have been designed with the user in mind to make glucose testing easier, and “provide reliable results at an affordable cost”.
